Greater Munich Metropolitan Area
• Team lead (HTA/HEOR & Pricing), including capability building and resource planning • Lead responsibility for AMNOG dossier preparation and price negotiation planning and preparation with GKV-SV • Member of extended leadership team; delegate to vfa working group on HTA methodology and EU HTA readiness
• Expanded responsibility for a broader product portfolio including ultra-orphan launch • Oversaw full pre-launch Market Access processes across multiple indications, ensuring access readiness at launch • Contributed to core processes (e.g., controlled distribution, HEOR projects, governmental affairs, ...)
• Project lead for AMNOG dossier development, G-BA advice, benefit assessment and price negotiation preparation, including lateral leadership of cross-functional teams and management of supporting consultancies • Drove key non-AMNOG access activities such as HEOR projects, reimbursement clarification initiatives (in- and outpatient) and NUB/OPS applications
Planning and writing of AMNOG dossiers (module 1-5) and support of clients in AMNOG process: • G-BA advice requests, Advisory Boards/workshops, briefing books for oral hearings • Preparation of workshops, development of AMNOG strategy, preparation of statistical analysis plans (SAP), analyses of clinical studies and cost analysis, systematic literature/register research (SLR/SRR), medical writing • Dealing with health policy challenges (e.g. changes in G-BA VerfO) and developing market access scenarios for innovative products (e.g. gene therapies)
Planning and writing of AMNOG dossiers (module 1-5) and support of clients in AMNOG process: • G-BA advice requests, Advisory Boards/workshops, briefing books for oral hearings • Preparation of workshops, development of AMNOG strategy, preparation of statistical analysis plans (SAP), analyses of clinical studies and cost analysis, systematic literature/register research (SLR/SRR), medical writing • Dealing with health policy challenges (e.g. changes in G-BA VerfO) and developing market access scenarios for innovative products (e.g. gene therapies)
Marketing, Medical, Market Access (mainly AMNOG, pricing models, landscaping). Therapeutic areas – oncology/hematology: acute myeloid leukemia (AML), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC). Therapeutic areas - others: inflammatory bowel diseases (IBD), migraine, cutaneous and systemic lupus erythematodes (CLE/SLE), rheumatoid arthritis (RA) and heart failure (HF)
Improvement of biorefinery byproducts through sustainable and integrated closed loop biorefinery systems. Development of enzyme systems to produce oligosaccharides as prebiotics to be used in functional food or healthcare.
Small consulting/research projects in teams of 4-6 other research scholars/consultants from around the globe with various academic backgrounds to consult Fortune 500 companies (mainly healthcare companies) regarding emerging trends , technologies, and markets. Team-lead since 08/2015.